J&J's Doxil faces FDA setback in breast cancer in US
This article was originally published in Scrip
Executive Summary
Johnson & Johnson (Centocor Ortho Biotech) has suffered a setback with a second cancer drug in a day, after receiving another complete response letter for anthracycline chemotherapy drug Doxil (doxorubicin HCI liposome injection) to treat women with locally advanced and metastatic breast cancer.